The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2017

Filed:

Feb. 24, 2015
Applicant:

Arbutus Biopharma Corporation, Burnaby, CA;

Inventors:

Muthiah Manoharan, Cambridge, MA (US);

Kallanthottathil G. Rajeev, Cambridge, MA (US);

Muthusamy Jayaraman, Cambridge, MA (US);

David Butler, Cambridge, MA (US);

Jayaprakash K. Nair, Cambridge, MA (US);

Martin Maier, Cambridge, MA (US);

Laxman Eltepu, Cambridge, MA (US);

Assignee:

Arbutus Biopharma Corporation, Burnaby, British Columbia, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 9/127 (2006.01); C07C 229/30 (2006.01); A61K 31/713 (2006.01); C07D 203/10 (2006.01); C07C 229/08 (2006.01); C07D 317/28 (2006.01); C07D 319/06 (2006.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01); C12N 15/11 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/20 (2006.01); A61K 47/28 (2006.01); C07C 237/16 (2006.01); C07C 251/38 (2006.01); C07C 251/78 (2006.01); C07C 271/12 (2006.01); C07C 271/20 (2006.01); C07C 323/25 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 9/1272 (2013.01); A61K 31/713 (2013.01); A61K 39/00 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/20 (2013.01); A61K 47/28 (2013.01); C07C 229/08 (2013.01); C07C 229/30 (2013.01); C07C 237/16 (2013.01); C07C 251/38 (2013.01); C07C 251/78 (2013.01); C07C 271/12 (2013.01); C07C 271/20 (2013.01); C07C 323/25 (2013.01); C07D 203/10 (2013.01); C07D 317/28 (2013.01); C07D 319/06 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/32 (2013.01);
Abstract

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein Rand Rare each independently for each occurrence optionally substituted C-Calkyl, optionally substituted C-Calkenyl, optionally substituted C-Calkynyl, optionally substituted C-Cacyl, or -linker-ligand; Ris H, optionally substituted C-Calkyl, optionally substituted C-Calkenyl, optionally substituted C-Calkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40 K), optionally substituted mPEG (mw 120-40 K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)N(Q), S(O), N(Q)S(O), SS, O═N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalky, ω-phosphoalkyl or ω-thiophosphoalkyl.


Find Patent Forward Citations

Loading…